Population screening for colorectal cancer means getting FIT: The past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT)

Gut and Liver

Volumn 8, Issue 2, 2014, Pages 117-130

  Allison, James E ^a,b   Fraser, Callum G ^c   Halloran, Stephen P ^d   Young, Graeme P ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIVISION OF RESEARCH   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

Colorectal cancer; Colorectal cancer screening; Fecal immunochemical test for hemoglobin; Population screening

Indexed keywords

HEME; HEMOGLOBIN;

ANALYTICAL EQUIPMENT; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; FALSE POSITIVE RESULT; FECES ANALYSIS; FECES LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOCHEMISTRY; IMMUNOFLUORESCENCE TEST; MASS SCREENING; MEDICAL TERMINOLOGY; NONHUMAN; OCCULT BLOOD; POINT OF CARE TESTING; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROTEIN STABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; CHEMISTRY; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; FECES; FORECASTING; HEALTH; PROCEDURES; SENSITIVITY AND SPECIFICITY; TRENDS;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FORECASTING; GLOBAL HEALTH; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; MASS SCREENING; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 84896996529     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2014.8.2.117     Document Type: Review

References (85)

1. Potter MB. Strategies and resources to address colorectal cancer screening rates and disparities in the United States and globally. Annu Rev Public Health 2013;34:413-429.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
4. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59:366-378.
5. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477. (Pubitemid 26400242)
6. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471. (Pubitemid 26400241)
7. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-1607. (Pubitemid 32162983)
8. Hoff G, Grotmol T, Skovlund E, Bretthauer M; Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009;338:b1846.
9. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-1633.
10. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial: SCORE. J Natl Cancer Inst 2011;103:1310-1322.
11. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345-2357.
12. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-1114.
13. Segnan N, Patnick J, von Karsa L; European Commission Directorate General for Health & Consumers; International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. Luxembourg: Publications Office of the European Union, 2010.
14. Halloran SP, Launoy G, Zappa M; International Agency for Research on Cancer. European guidelines for quality assurance in colorectal cancer screening and diagnosis: first Edition: faecal occult blood testing. Endoscopy 2012;44 Suppl 3:SE65-SE87.
15. Imperiale TF. Noninvasive screening tests for colorectal cancer. Dig Dis 2012;30 Suppl 2:16-26.
16. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-1595. (Pubitemid 351615355)
17. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-1227.
18. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005;128:192-206. (Pubitemid 40039970)
19. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001;175:195-198. (Pubitemid 32791339)
20. Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-122. (Pubitemid 38296846)
21. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med 2012;55:87-92.
22. Digby J, McDonald PJ, Strachan JA, Libby G, Steele RJ, Fraser CG. Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme. J Med Screen 2013;20:80-85.
23. Fleisher M, Winawer SJ, Zauber AG, Smith C, Schwartz MK. Accuracy of fecal occult blood test interpretation. National Polyp Study Work Group. Ann Intern Med 1991;114:875-6.
24. Niv Y. Fecal occult blood test: the importance of proper evaluation. J Clin Gastroenterol 1990;12:393-395. (Pubitemid 20234366)
25. Burtonwood C, Butler P, Young M, Halloran S. Monitoring faecal occult blood test positivity in the NHS bowel cancer screening programme. Gut 2012;61:A334.
26. Steele RJ, McDonald PJ, Digby J, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United Eur Gastroenterol J 2013;1:198-205.
27. Stegeman I, de Wijkerslooth TR, Stoop EM, et al. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut 2014;63:466-471.
28. Simon JB. Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology 1985;88:820-837. (Pubitemid 15130675)
29. Barrows GH, Burton RM, Jarrett DD, Russell GG, Alford MD, Songster CL. Immunochemical detection of human blood in feces. Am J Clin Pathol 1978;69:342-346. (Pubitemid 8306794)
30. Songster CL, Barrows GH, Jarrett DD. Immunochemical detection of human fecal occult blood. In: Schottenfeld D, Sherlock P, Winawer SJ, eds. Colorectal cancer, prevention, epidemiology, and screening. Volume 13. New York: Raven Press, 1980:193-204.
31. Songster CL, Barrows GH, Jarrett DD. Immunochemical detection of fecal occult blood: the fecal smear punch-disc test: a new noninvasive screening test for colorectal cancer. Cancer 1980;45(5 Suppl):1099-1102.
32. Vellacott KD, Baldwin RW, Hardcastle JD. An immunofluorescent test for faecal occult blood. Lancet 1981;1:18-19. (Pubitemid 11200331)
33. St John DJ, Young GP, Alexeyeff MA, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993;104:1661-1668. (Pubitemid 23235456)
34. Williams JA, Hunter R, Smith M, Coles ME, Hubert TW, Thomas DW. Evaluation of an immunological test for occult bleeding from colorectal neoplasia. Aust N Z J Surg 1982;52:617-621. (Pubitemid 13056282)
35. Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg 1994;81:448-451. (Pubitemid 24124835)
36. Rozen P, Knaani J, Papo N. Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia. Eur J Cancer Prev 1995;4:475-481.
37. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-159. (Pubitemid 26017953)
38. Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol 1994;3:27-36. (Pubitemid 24171938)
39. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462-1470.
40. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-255. (Pubitemid 351650610)
41. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-428. (Pubitemid 41096630)
42. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-2025.
43. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90. (Pubitemid 351899018)
44. Allison JE. The imperative of equal funding for studies that evaluate any of the evidence-based, guideline-recommended colorectal cancer screening tests. Clin Gastroenterol Hepatol 2009;7:1269-1271.
45. Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res 1996;87:1011-1124.
46. Saito H, Soma Y, Koeda J, et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer 1995;61:465-469.
47. Shimbo T, Glick HA, Eisenberg JM. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Health Care 1994;10:359-375. (Pubitemid 24222536)
48. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980;64:1263-1272. (Pubitemid 10100344)
49. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther 2006;23:1359-1364.
50. Young GP, Fraser CG, Halloran SP, Cole S. Guaiac based faecal occult blood testing for colorectal cancer screening: an obsolete strategy? Gut 2012;61:959-960.
51. Fletcher RH. Commentary. ACP J Club 1996;124:74.
52. Cole SR, Tucker GR, Osborne JM, et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust 2013;198:327-330.
53. Ventura L, Mantellini P, Grazzini G, et al. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis 2014;46:82-86.
54. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-669.
55. National Colorectal Cancer Roundtable. Tools & resources: the new FOBT clinician's reference resource [Internet]. [place unknown]: National Colorectal Cancer Roundtable, c2002 [cited 2013 Sep 27]. Available from: http://nccrt.org/about/providereducation/fobt-clinicians-reference-resources.
56. Qaseem A, Denberg TD, Hopkins RH Jr, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012;156:378-386.
57. Sugerman DT. JAMA Patient Page: options for colorectal cancer screening. JAMA 2013;310:658.
58. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706.
59. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology 2012;142:422-424.
60. Fraser CG, Allison JE, Young GP, Halloran SP. Newer fecal tests: opportunities for professionals in laboratory medicine. Clin Chem 2012;58:963-965.
61. Fraser CG, Halloran SP, Allison JE, Young GP. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT). Clin Chem Lab Med 2013:1-3.
62. Fraser CG, Allison JE, Halloran SP, Young GP; Expert Working Group on Fecal Immunochemical Tests for Hemoglobin, Colorectal Cancer Screening Committee, World Endoscopy Organization. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 2012;104:810-814.
63. Fraser CG, Allison JE, Young GP, Halloran SP. Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Clin Gastroenterol Hepatol 2013;11:839-840.
64. Tao S, Seiler CM, Ronellenfitsch U, Brenner H. Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer. Acta Oncol 2013;52:1667-1675.
65. Grazzini G, Ventura L, Zappa M, et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 2010;59:1511-1515.
66. van Roon AH, Hol L, van Vuuren AJ, et al. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol 2012;107:99-107.
67. NHS Bowel Cancer Screening Southern Programme Hub (BCSP). Evaluation of quantitative faecal immunochemical tests for haemoglobin [Internet]. Surrey: NHS BCSP; 2013 [cited 2014 Feb 3]. Available from: http://www.worldendo.org/assets/ downloads/pdf/activities/fit-reports/gmec-fit-evaluation-report.pdf.
68. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-68.
69. Steele RJ, McClements PL, Libby G, et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009;58:530-535.
70. Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 2012;142:497-504.
71. van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013;62:409-415.
72. Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012;10:633-638.
73. Potter MB, Ackerson LM, Gomez V, et al. Effectiveness and reach of the FLU-FIT program in an integrated health care system: a multisite randomized trial. Am J Public Health 2013;103:1128-1133.
74. Potter MB, Gildengorin G, Wang Y, Wu M, Kroon L. Comparative effectiveness of two pharmacy-based colorectal cancer screening interventions during an annual influenza vaccination campaign. J Am Pharm Assoc (2003) 2010;50:181-187.
75. Potter MB, Phengrasamy L, Hudes ES, McPhee SJ, Walsh JM. Offering annual fecal occult blood tests at annual flu shot clinics increases colorectal cancer screening rates. Ann Fam Med 2009;7:17-23.
76. Potter MB, Somkin CP, Ackerson LM, et al. The FLU-FIT program: an effective colorectal cancer screening program for high volume flu shot clinics. Am J Manag Care 2011;17:577-583.
77. Walsh JM, Gildengorin G, Green LW, Jenkins J, Potter MB. The FLU-FOBT Program in community clinics: durable benefits of a randomized controlled trial. Health Educ Res 2012;27:886-894.
78. Zajac IT, Whibley AH, Cole SR, et al. Endorsement by the primary care practitioner consistently improves participation in screening for colorectal cancer: a longitudinal analysis. J Med Screen 2010;17:19-24.
79. Hewitson P, Ward AM, Heneghan C, Halloran SP, Mant D. Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial. Br J Cancer 2011;105:475-480.
80. van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011;9:333-339.
81. Raginel T, Puvinel J, Ferrand O, et al. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology 2013;144:918-925.
82. Imperiale TF. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med 2007;146:309-311. (Pubitemid 351650618)
83. Fraser CG. A future for faecal haemoglobin measurements in the medical laboratory. Ann Clin Biochem 2012;49(Pt 6):518-526.
84. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010;105:2457-2464.
85. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, et al. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) 2011;4:1563-1571.